$^{86/90}$Y-based theranostics targeting angiogenesis in a murine breast cancer model

Emily B. Ehlerding[1], Carolina A. Ferreira[2], Eduardo Aluicio-Sarduy[1], Dawei Jiang[3], Hye Jin Lee[4], Charles P. Theuer[5], Jonathan W. Engle[1], Weibo Cai[1-4,6,*]

[1]Department of Medical Physics, University of Wisconsin – Madison

[2]Department of Biomedical Engineering, University of Wisconsin – Madison

[3]Department of Radiology, University of Wisconsin – Madison

[4]Pharmaceutical Sciences Department, University of Wisconsin – Madison

[5]TRACON Pharmaceuticals, Inc.

[6]Carbone Comprehensive Cancer Center, University of Wisconsin – Madison



Figure S1. PET imaging of ^{86}Y-DTPA-IgG. (A) Serial representative MIP images. (B) *Ex vivo* biodistribution results, n=4.



Figure S2. Results of toxicity monitoring. (A) Body weights of all mice were measured every other day. (B) Complete blood count analyses from mice injected with ^{90}Y-DTPA-TRC105. N=5-6 per group.



Figure S3. Histological evaluation of tissues from therapeutic groups at 14 days post-injection.

Table S1. PET ROI data following injection of ^{86}Y-DTPA-TRC105, in %ID/g, n=4.

Organ	30 min	12 h	24 h	48 h
Heart	19.53 ± 4.10	12.10 ± 2.52	12.60 ± 0.10	9.13 ± 1.73
Liver	14.25 ± 3.36	8.75 ± 1.19	9.80 ± 0.30	7.13 ± 0.93
Spleen	9.03 ± 2.01	6.90 ± 1.38	8.00 ± 1.40	6.43 ± 1.61
Tumor	2.28 ± 0.55	8.10 ± 0.95	9.60 ± 0.30	9.13 ± 1.05
Muscle	1.53 ± 0.31	1.58 ± 0.18	1.95 ± 0.05	1.48 ± 0.19
Brain	2.08 ± 0.41	1.65 ± 0.46	1.55 ± 0.05	1.35 ± 0.33

Table S2. PET ROI data following injection of ^{86}Y-DTPA-IgG, in %ID/g, n=4.

Organ	30 min	12 h	24 h	48 h
Heart	22.08 ± 3.51	14.58 ± 2.97	12.43 ± 2.43	10.90 ± 2.60
Liver	15.43 ± 2.57	9.83 ± 1.66	9.20 ± 1.59	8.10 ± 1.43
Spleen	7.98 ± 2.06	7.60 ± 1.63	7.20 ± 1.69	6.70 ± 1.74
Tumor	2.55 ± 0.81	7.98 ± 1.14	8.58 ± 1.31	8.63 ± 1.59
Muscle	1.65 ± 0.35	1.78 ± 0.57	1.75 ± 0.63	1.65 ± 0.48
Brain	2.80 ± 0.29	2.05 ± 0.54	2.15 ± 0.30	1.80 ± 0.32